|
Improving Memory in Patients with Multiple Sclerosis Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Improving Memory in Patients with Multiple Sclerosis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Improving Memory in Patients with Multiple Sclerosis Clinical research trials and Improving Memory in Patients with Multiple Sclerosis health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Improving Memory in Patients with Multiple Sclerosis. Improving Memory in Patients with Multiple Sclerosis Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Improving Memory in Patients with Multiple Sclerosis clinical trial. Subjects frequently get the best healthcare possible for their Improving Memory in Patients with Multiple Sclerosis condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Improving Memory in Patients with Multiple Sclerosis  Improving Memory in Patients with Multiple Sclerosis
Improving Memory in Patients with Multiple Sclerosis
For Condition: Multiple Sclerosis
Status: Recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) , Department of Education
Synopsis: People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer’s disease.
Details: Cognitive dysfunction is one of the leading causes of disability in people with MS. Memory involving specific words (verbal memory) is particularly affected in individuals with MS. Attempts to rehabilitate cognitive dysfunction in MS have had only limited success. This study will determine the efficacy of donepezil therapy and glucose administration for enhancing verbal memory functioning in individuals with MS. The study will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention. Forty participants with MS will be randomly assigned to receive either donepezil or placebo for 24 weeks. Participants will complete memory and cognitive tests at the beginning and end of the 24 week period. Twenty participants with MS will be randomly assigned to drink a beverage sweetened with either glucose or saccharin (placebo). Participants will then complete memory and other cognitive tests. Two weeks later, participants will drink a beverage sweetened with the alternative sweetener and again complete the memory and cognitive tests.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/56 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - MS as defined by the Poser criteria - Expanded Disability Status Scale (EDSS) score of 0 to 6.5 - Stable neurologic function for at least 30 days prior to study entry - Agree to continue all current medications for study duration - Rey Auditory Verbal Learning Test score in low normal range or below - Mini-mental status exam score of 26 or higher - Montgomery-Asberg Depression Scale scaled score of 14 or lower - Fluent in English Exclusion Criteria - Use of anticholinergic or benzodiazepine medication - Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry - Current alcohol or substance abuse - History of neurological or major medical problem that has a known effect on cognitive functioning - History of noncompliance - Visual or upper extremity impairment which precludes ability to participate in cognitive assessment
Total Enrollment: 60
Location and Contact Information:
Overall Study Official:
LaurenKrupp, Principal Investigator, Department of Neurology, University Hospital Medical Center
University Hospital and Medical Center *Recruiting*
Stony Brook, New York, 11794-8121
United States
Recruiting Patricia Melville 631-444-8164
Additional Information:
Study ID Numbers: 1R01 HD38107-01;
Study Start Date: September 1999
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00062972
Other Multiple Sclerosis Studies:
1. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis
2. Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
3. Induction Therapy with a Single High Dose Bolus of Intravenous Methotrexate with Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting with a First Acute Demyelinating Event.
4. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
5. Comparison of safety and efficacy of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
Related Studies:
Other Multiple Sclerosis Clinical Trials
Other New York Clinical Trials
Other Stony Brook Clinical Trials
Improving Memory in Patients with Multiple Sclerosis
|
|
|
|
|
|
|
|
